3d Medicines, Inc.HKEX: 1244

3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted

Jan 9, 2026 at 3:15 PM UTC · Issued by 3d Medicines, Inc.

3D Medicines Inc HKEX:1244:

NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NMPA

Earlier from 3d Medicines